Glow Lifetech Corp. (GLWLF)
USD 0.04
(-10.06%)
USD 0.04
(-10.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 87.66 Thousand USD | -19.36% |
| 2022 | 108.7 Thousand USD | 244.35% |
| 2021 | 31.56 Thousand USD | 393.25% |
| 2020 | 6400.00 USD | 0.0% |
| 2019 | 6400.00 USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 52.85 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 305.12 Thousand USD | 255.76% |
| 2024 Q2 | 262.69 Thousand USD | -13.02% |
| 2023 Q1 | 501.62 Thousand USD | 5.93% |
| 2023 Q4 | 87.66 Thousand USD | -88.96% |
| 2023 Q3 | 794.22 Thousand USD | 10.16% |
| 2023 Q2 | 720.98 Thousand USD | 43.73% |
| 2023 FY | 87.66 Thousand USD | -19.36% |
| 2022 Q2 | 12.34 Thousand CAD | -35.46% |
| 2022 Q1 | 19.12 Thousand CAD | -39.42% |
| 2022 Q4 | 473.53 Thousand USD | 21.83% |
| 2022 FY | - USD | 244.35% |
| 2022 Q3 | 388.69 Thousand USD | 3049.12% |
| 2021 Q1 | - CAD | -100.0% |
| 2021 FY | 31.56 Thousand USD | 393.25% |
| 2021 Q4 | 31.56 Thousand CAD | 0.0% |
| 2021 Q3 | - CAD | 0.0% |
| 2021 Q2 | - CAD | 0.0% |
| 2020 FY | 6400.00 USD | 0.0% |
| 2020 Q4 | 6400.00 CAD | 0.0% |
| 2020 Q3 | 6400.00 CAD | 0.0% |
| 2020 Q2 | 6400.00 CAD | 0.0% |
| 2020 Q1 | 6400.00 CAD | 0.0% |
| 2019 FY | 6400.00 USD | 0.0% |
| 2019 Q4 | 6400.00 CAD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2017 FY | 52.85 Thousand USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.787% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 97.873% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.681% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.798% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.706% |
| Mesoblast Limited | 118.7 Million USD | 99.926% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 90.756% |
| Genus plc | 233.1 Million USD | 99.962% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 97.009% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 93.476% |
| Marizyme, Inc. | 18.71 Million USD | 99.532% |
| ContraFect Corporation | 2.88 Million USD | 96.957% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 88.312% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 35.3% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 93.939% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 96.231% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 98.451% |
| MultiCell Technologies, Inc. | 202.58 USD | -43171.794% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.848% |
| EV Biologics, Inc. | 1.49 Million USD | 94.135% |
| Q BioMed Inc. | 4.1 Million USD | 97.867% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.735% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 86.087% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 92.864% |
| Biomind Labs Inc. | 735.54 Thousand USD | 88.082% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.949% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.326% |
| Skye Bioscience, Inc. | 4.61 Million USD | 98.101% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 90.129% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 38.057% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 98.507% |
| IMV Inc. | 28.88 Million USD | 99.697% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -240.838% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 96.118% |
| GB Sciences, Inc. | 1.75 Million USD | 95.017% |
| Alpha Cognition Inc. | 1.22 Million USD | 92.817% |
| HST Global, Inc. | 98.31 Thousand USD | 10.841% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Halberd Corporation | 150 Thousand USD | 41.56% |
| Enzolytics Inc. | 996.33 Thousand USD | 91.202% |
| Resverlogix Corp. | 6.49 Million USD | 98.65% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 81.642% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 65.703% |
| argenx SE | 20 Million USD | 99.562% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.808% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 96.764% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -757.311% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.979% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 56.305% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 96.344% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 61.769% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.87% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 97.103% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 75.63% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.569% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 41.031% |
| BioStem Technologies, Inc. | 4.71 Million USD | 98.139% |
| ONE Bio Corp. | 19.71 Million USD | 99.555% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 64.962% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 64.756% |
| Agentix Corp. | 50 Thousand USD | -75.32% |
| LadRx Corporation | 33.6 Thousand USD | -160.846% |
| Cell Source, Inc. | 9.25 Million USD | 99.053% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 88.408% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 88.408% |
| NovAccess Global Inc. | 2.19 Million USD | 96.015% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.761% |
| Itoco Inc. | 228.37 Thousand USD | 61.616% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 58.45% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 98.241% |
| Kadimastem Ltd | 891.22 Thousand USD | 90.164% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 78.186% |
| CytoDyn Inc. | 30.07 Million USD | 99.709% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 81.899% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 75.086% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 98.879% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 28.441% |
| Rebus Holdings, Inc. | 310 Thousand USD | 71.723% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 98.149% |
| International Stem Cell Corporation | 4.17 Million USD | 97.902% |
| Bioxytran, Inc. | 1.92 Million USD | 95.446% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -40.452% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 95.981% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.946% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.979% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 94.364% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 67.291% |
| Neutra Corp. | 54.15 Thousand USD | -61.866% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 95.21% |
| PureTech Health plc | 25.51 Million USD | 99.656% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 92.84% |
| IXICO plc | 472.02 Thousand USD | 81.429% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.434% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.859% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.906% |